Advertisement

Advertisement

colorectal cancer
immunotherapy

ESMO 2018: Small Study of Preoperative Nivolumab Plus Ipilimumab in dMMR Colon Cancer

Neoadjuvant treatment with a combination of the immune checkpoint inhibitors nivolumab (Opdivo) and ipilimumab (Yervoy) achieved major pathological responses in mismatch repair­–deficient (dMMR) early-stage colon cancers, according to results reported by Chalabi et al at the European...

colorectal cancer
sarcoma

FDA Approves Levoleucovorin for Treatment in Osteosarcoma, Colorectal Cancer

The U.S. Food and Drug Administration (FDA) recently approved levoleucovorin (Khapzory) injection, a folate analog, for three indications: rescue after high-dose methotrexate therapy in patients with osteosarcoma; diminishing the toxicity associated with overdosage of folic acid...

colorectal cancer

Dutch Study of Postoperative Outcomes With Screening- vs Nonscreening-Detected Colon and Rectal Cancers

In a Dutch study reported in JAMA Surgery, de Neree tot Babberich et al found that postoperative outcomes were better in patients with colon cancer, but not rectal cancer, detected vs not detected through the national fecal immunochemical test–based screening program.    Study ...

colorectal cancer
issues in oncology

Sex-Linked Differences in Cancer May Identify Specific Genetic Drivers, Predict Responses to Treatment

Analysis of male- and female-derived tumor samples revealed differences in prognostic biomarkers, genes that drive cancer, and in regulation of key pathways that may predict responses to treatment, according to results published in two studies in Cancer Research, one by Li et al and the other...

colorectal cancer

First-Line EGFR Inhibitor Plus FOLFOX4 in RAS Wild-Type Metastatic Colorectal Cancer

In the Chinese phase III TAILOR trial reported in the Journal of Clinical Oncology, Qin et al found that adding the EGFR inhibitor cetuximab to FOLFOX4 (fluorouracil, leucovorin, oxaliplatin) improved progression-free survival in patients with RAS wild-type metastatic colorectal cancer. Study...

Colorectal Cancer

Triplet Combination for Advanced Anal Squamous Cell Carcinoma

In a French phase II trial reported in The Lancet Oncology, Stefano Kim, MD, of the Department of Oncology, University Hospital of Besancon, and colleagues found that treatment with docetaxel, cisplatin, and fluorouracil (DCF) was active in patients with metastatic or unresectable locally...

Gastrointestinal Cancer
Colorectal Cancer

Maintenance Therapy for Metastatic Colorectal Cancer: Benefit Seen With Panitumumab Combination

Although the optimal approach to maintenance is not definitive in patients with metastatic colorectal cancer who have undergone chemotherapy-based induction with anti–endothelial growth factor receptor (EGFR) agents, the phase II VALENTINO trial showed that anti-EGFR maintenance therapy with...

colorectal cancer
gynecologic cancer

PMS2-Associated Lynch Syndrome and Cancer Risks

In a study reported in the Journal of Clinical Oncology, ten Broeke et al found that patients with Lynch syndrome associated with PMS2 mutation are at increased risk of colorectal and endometrial cancers but not other cancers associated with the syndrome. As noted by the investigators, Lynch...

colorectal cancer

Genetic Forecasting May Predict Response to Cetuximab in Colorectal Cancer

Blood tests could predict how long it takes until colorectal cancer becomes resistant to treatment based on the same principle used in forecasting the weather, a new study by Khan et al in Cancer Discovery has found. The liquid biopsies could also predict patients that are unlikely to initially...

Gastrointestinal Cancer
Colorectal Cancer

Ipilimumab in Combination With Nivolumab for MSI-H or dMMR Metastatic Colorectal Cancer

On July 10, 2018, ipilimumab (Yervoy) was granted accelerated approval for use in combination with nivolumab (Opdivo) for the treatment of patients at least 12 years of age with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer progressing...

colorectal cancer

Sequential Liquid Biopsy Sampling May Be a Predictive Tool for Early Disease Progression in Patients With Colorectal Cancer

According to the American Cancer Society, excluding skin cancers, colorectal cancer is the third most common cancer among men and women in the United States, with over 97,000 new cases expected this year, and is the third leading cause of cancer-related death, with over 50,000 deaths predicted in...

Colorectal Cancer

ERBB2/ERBB3-Mutant Colorectal Cancer

A study reported in the Journal of the National Cancer Institute by Loree and colleagues found that ERBB2/ERBB3 mutations in colorectal cancer are associated with microsatellite instability and PIK3CA mutation. Kanwal Raghav, MD, MBBS, of the Division of Gastrointestinal Medical Oncology, The...

colorectal cancer
immunotherapy

FDA Grants Breakthrough Therapy Designation for Encorafenib Plus Binimetinib and Cetuximab in BRAF V600E–Mutant Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for encorafenib (Braftovi) in combination with binimetinib (Mektovi) and cetuximab (Erbitux) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC), as detected by...

Colorectal Cancer
Survivorship

ACS Nutrition and Physical Activity Guidelines for Cancer Survivors and Outcomes After Colon Cancer Diagnosis

IN A STUDY reported in JAMA Oncology, Erin L. Van Blarigan, ScD, of the University of California, San Francisco, and colleagues found that adherence to American Cancer Society (ACS) nutrition and physical activity guidelines for cancer survivors was associated with improved survival among patients ...

Colorectal Cancer

BRAF Mutations, Survival, and Recurrence in Patients With Colorectal Cancer Liver Metastases

In a study reported in JAMA Surgery by Margonis and colleagues, the presence of a BRAF V600E mutation was associated with a higher risk of recurrence and poorer overall survival among patients undergoing surgical resection of liver metastases from colorectal cancer. Matthew J. Weiss, MD, of the...

colorectal cancer

Study Examines Right-Sided vs Left-Sided Colon Cancer Survival Rates

Patients with colorectal cancer tumors on the right side may have poorer 5-year survival rates than those whose tumors are located on the left side. However, a new large-scale retrospective study is the first to demonstrate a potential improvement of these outcomes. Study results show that nearly...

breast cancer
colorectal cancer
prostate cancer

Following a Healthy Diet and Avoiding Alcohol May Reduce Overall Cancer Risk

The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) has estimated that in developed countries, about 35% of breast cancers and 45% of colorectal cancers could be prevented with a better adherence to nutritional recommendations. A large prospective study evaluating...

colorectal cancer

By Sending Tests by Mail, Researchers Boost Colorectal Cancer Screening Rates Among Medicaid Patients

Mailing colorectal cancer screening tests to patients insured by Medicaid increased screening rates for this population, reported researchers at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center. In collaboration with the Mecklenburg County Health Department in...

colorectal cancer
kidney cancer
hepatobiliary cancer
lung cancer
pancreatic cancer
issues in oncology
bladder cancer

Large Disparities in Cancer Mortality Rates Found Among Different Racial/Ethnic Populations in New York State

According to the American Cancer Society, cancer is the leading cause of death for Hispanics and Asian/Pacific Islanders in the United States. However, their cancer burden is less than that of non-Hispanic whites and especially non-Hispanic blacks, who bear the most disproportionate share of the...

colorectal cancer

Docetaxel, Cisplatin, and Fluorouracil in Advanced Anal Squamous Cell Carcinoma

In a French phase II trial reported in The Lancet Oncology, Kim et al found that treatment with docetaxel, cisplatin, and fluorouracil (DCF) was active in patients with metastatic or unresectable locally recurrent anal squamous cell carcinoma. Study Details The multicenter study included 66...

Colorectal Cancer
Immunotherapy

Nivolumab Plus Low-Dose Ipilimumab Approved for Second-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

On July 11, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal...

palliative care
colorectal cancer
lung cancer
cost of care

Geographic Differences in End-of-Life Cancer Care

When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found differences in this type of cancer care across different parts of the country. The findings, published by Keating et al...

colorectal cancer
immunotherapy

FDA Approves Nivolumab Plus Low-Dose Ipilimumab for Second-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

Today, the U.S. Food and Drug Administration (FDA) approved  nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR)...

colorectal cancer

Vitamin D Levels and Colorectal Cancer Risk

In a study reported in the Journal of the National Cancer Institute, McCullough et al found reduced risk for colorectal cancer with increasing levels of circulating 25-hydroxyvitamin D (25[OH]D). Study Details The study was an international pooling project using participant-level data from 17...

colorectal cancer

Colon Cancer Surgery and Resource Availability at Hospitals on Weekends and Holidays

The likelihood of severe complications after emergency colon cancer surgery is significantly higher over the weekend, according to a study published by Huijts et al in JNCCN – Journal of the National Comprehensive Cancer Network. The research was led by Perla Marang-van de Mheen, PhD, of the...

colorectal cancer
survivorship

Dietary Insulin Load and Risk of Disease Recurrence in Stage III Colon Cancer

New research led by Dana-Farber Cancer Institute investigators suggests that patients treated for nonmetastatic colon cancer may sharply reduce the risk that the disease will return by following a diet low in carbohydrates and other foods that raise insulin levels. In a study published by...

colorectal cancer
cost of care

AMA Plans Advocacy Outreach to Expand Colorectal Screening

Building on the efficacy of colorectal cancer screening, the American Medical Association (AMA) endorsed a plan at its Annual Meeting to work with physicians and payers to make the screening more available and affordable. Challenges with insurance coverage remain a barrier to colorectal cancer...

Solid Tumors
Gastrointestinal Cancer
Colorectal Cancer

Care for Colorectal Cancer Costs Twice as Much in Western Washington vs British Columbia, With Similar Survival

It is widely acknowledged that the costs of cancer care are much higher in the United States than in Canada, with outcomes that are thought to be similar. A new study presented at the 2018 ASCO Annual Meeting supports that view, by documenting and quantifying the differences in health-care costs...

Solid Tumors
Gastrointestinal Cancer
Colorectal Cancer

Less Is More: No Benefit Reported for Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer

With a growing emphasis on value in cancer care, some types of resource-intensive therapies may need to be reconsidered. One such treatment may be hyperthermic intraperitoneal chemotherapy, which showed no benefit during surgery for colorectal cancer confined to the peritoneum in the PRODIGE 7...

colorectal cancer

Surveillance Intensity Not Associated With Earlier Detection of Recurrence or Improved Survival in Patients With Colorectal Cancer

A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of posttreatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II, or III colorectal cancer. Published by...

Solid Tumors
Colorectal Cancer

Following Guidelines for Healthy Eating and Physical Activity May Improve Survival in Patients Treated for Colon Cancer

Following guidelines for proper nutrition, maintaining a healthy weight, and staying physically active may improve survival among patients treated for colon cancer, according to the results of a study with nearly 1,000 patients followed for a median of 7 years.1 “The study suggests that if...

colorectal cancer

Young-Onset Colorectal Cancer Survivors, Patients, and Caregivers Asked to Participate in Third Annual Survey

The Colorectal Cancer Alliance has opened its third annual international survey of young-onset colorectal cancer patients, survivors, and caregivers, with the intent of learning about and tracking the medical and psychosocial experiences of this often overlooked group, which comprises 11% of...

colorectal cancer

Validation of the Consensus Immunoscore for Classification of Colon Cancer

As reported in The Lancet by Pagès et al, an international collaboration has validated the consensus Immunoscore for colon cancer as a predictive tool for recurrence of disease. Study Details An international consortium of 14 centers in 13 countries, led by the Society for Immunotherapy of ...

colorectal cancer
immunotherapy

Howard S. Hochster, MD, on Colorectal Cancer: Results From the E7208 Trial

Howard S. Hochster, MD, of Rutgers-Cancer Institute of New Jersey, discusses study findings on irinotecan and cetuximab vs irinotecan, cetuximab, and ramucirumab as second-line therapy of advanced colorectal cancer following oxaliplatin and bevacizumab-based therapy (Abstract 3504).

colorectal cancer

Michael J. Overman, MD, and François Quenet, MD, on Colorectal Cancer: Results From the PRODIGE 7 Trial

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and François Quenet, MD, of the Institut Régional du Cancer de Montpellier, discuss phase III study findings on hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis (Abstract LBA3503).

colorectal cancer

2018 ASCO: Hyperthermic Intraperitoneal Chemotherapy Does Not Add Benefit in Patients With Advanced Colorectal Cancer

A randomized phase III clinical trial showed that people with advanced colorectal cancer may not need a frequently considered component of treatment—heated chemotherapy delivered to the abdomen during surgery. There was no difference in survival between patients with metastases in the abdomen ...

colorectal cancer
solid tumors
gynecologic cancer

2018 ASCO: Genomic Study Finds Lynch Syndrome Is Common Among Patients With MSI-High Tumors

A genomic study of more than 15,000 tumor samples showed that people who have tumors with high microsatellite instability (MSI-H)—a genomic marker associated with a large number of genetic mutations in the tumor—are more likely to have Lynch syndrome, a hereditary condition that...

colorectal cancer

American Cancer Society Updates Colorectal Cancer Screening Guideline

An updated American Cancer Society guideline now says colorectal cancer screening should begin at age 45 for people at average risk, based in part on data showing rates of colorectal cancer are increasing in young and middle-aged populations. The updated recommendations were published by Wolf et al ...

Colorectal Cancer

Risk of Recurrence in Stage III Colon Cancer According to RAS- and BRAF-Mutation Status

In a study in the PETACC-8 trial population reported in JAMA Oncology, Julien Taieb, MD, PhD, of the Université Paris Descartes, and colleagues found that the risk of recurrence in patients with stage III colon cancer differed for the primary tumor location according to RAS- and BRAF-mutation...

colorectal cancer

BRAF Mutations, Survival, and Recurrence in Patients Undergoing Surgery for Colorectal Cancer Liver Metastases

In a study reported in JAMA Surgery, Margonis et al found that presence of a BRAF V600E mutation was associated with higher risk of recurrence and poorer overall survival among patients undergoing surgical resection of liver metastases from colorectal cancer. Study Details The cohort study...

Colorectal Cancer
Breast Cancer
Hepatobiliary Cancer
Lung Cancer
Kidney Cancer
Prostate Cancer
CNS Cancers
Leukemia

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2018 Guidelines Updates

In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) covering 8 tumor types. Guidelines are now published for more than 60 tumor types and topics. Some of the key updates were presented at NCCN’s 23rd...

colorectal cancer

GAME Score for Patients With Metastatic Colorectal Cancer

Surgical oncologists at the Johns Hopkins University School of Medicine may have developed an improved scoring system for predicting survival in people with colorectal cancers that have metastasized to the liver. According to the researchers, the system, called the Genetic and Morphological...

colorectal cancer

Profile of ERBB2/ERBB3-Mutant Colorectal Cancer

In a study reported in the Journal of the National Cancer Institute, Loree et al found that ERBB2/ERBB3 mutations in colorectal cancer are associated with microsatellite instability and PIK3CA mutation. Study Details The study involved retrospective analysis of 419 patients from The University of ...

colorectal cancer

Survival Analysis for Adjuvant Chemotherapy vs Observation After Pathologic Complete Response and Resection in Rectal Cancer

In a propensity-score matching analysis reported in JAMA Oncology, Polanco et al found that adjuvant chemotherapy was associated with a survival benefit vs observation among patients with locally advanced rectal cancer who underwent resection after pathologic complete response following neoadjuvant ...

colorectal cancer

Adjuvant FOLFOX or CAPOX for 3 or 6 Months in Stage II or III Colon Cancer

As reported in the Journal of Clinical Oncology by Sobrero et al, the Italian phase III TOSCA trial did not demonstrate noninferiority of 3 vs 6 months of adjuvant CAPOX (capecitabine plus oxaliplatin) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) in relapse-free survival in stage II or...

colorectal cancer

Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer

A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients with stage III colorectal cancer, according to a new report published by Van Blarigan et al in JAMA Oncology. The findings...

Solid Tumors
Colorectal Cancer

Nut Consumption in Patients With Stage III Colon Cancer

People with stage III colon cancer who regularly eat tree nuts are at significantly lower risk of cancer recurrence and mortality than those who don’t, according to findings published by Fadelu et al in the Journal of Clinical Oncology.1 Study Findings The study followed 826 participants in the...

colorectal cancer

Adjuvant Chemotherapy Duration in Stage III Colon Cancer

In a preplanned pooled analysis of phase III trials reported in The New England Journal of Medicine, Grothey et al did not establish noninferiority of 3 vs 6 months of adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) in disease-free survival in...

colorectal cancer

Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

In a retrospective cohort study reported in JAMA Oncology, Cercek et al found evidence supporting the use of total neoadjuvant therapy as an effective option in locally advanced rectal cancer. Study Details The study involved data on 811 patients presenting with locally advanced rectal cancer (T3 ...

Breast Cancer
Colorectal Cancer
Survivorship

Expert Point of View: Timothy Gilligan, MD, MSc

“IN THE PAST, patients were often told to rest and reduce their physical activity during treatment, but we now know that exercise is both safe and beneficial,” said Timothy Gilligan, MD, MSc, moderator of a presscast where these results were presented prior to the Cancer Survivorship Symposium....

Advertisement

Advertisement

Advertisement